Focused On-demand Library for Oncostatin-M

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P13725

UPID:

ONCM_HUMAN

Alternative names:

Alternative UPACC:

P13725; Q6FHP8; Q9UCP6

Background:

Oncostatin-M, identified by its accession number P13725, plays a pivotal role as a growth regulator. It exhibits a dual function by inhibiting the proliferation of various tumor cell lines while simultaneously stimulating the proliferation of AIDS-KS cells. This protein is instrumental in cytokine production, including IL-6, G-CSF, and GM-CSF from endothelial cells, and operates through both type I and type II OSM receptors. Its involvement in fetal hepatocyte maturation underscores its significance in liver development and regeneration.

Therapeutic significance:

Understanding the role of Oncostatin-M could open doors to potential therapeutic strategies. Its unique ability to regulate cell proliferation and cytokine production positions it as a key target for developing treatments aimed at cancer, AIDS-related Kaposi's sarcoma, and liver diseases.